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Reimagining 
your Rx
VCU researchers are redesigning medicines. 
In the future, some prescriptions might 
be manufactured in a factory the size of a 
refrigerator – or even be produced by your body 
itself.
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Say “prescription medication,” and most people envision a one-size-fits-all white pill 
made in a huge factory far away.
While that picture of pharmaceutical production 
may be largely accurate for now, researchers 
at VCU are redesigning medicines. What will 
your future prescriptions look like? Some of 
them might be manufactured in a small portable 
factory – or even be produced by your body 
itself.
According to Dr. Thomas Roper, director 
of pharmaceutical engineering in VCU’s 
Department of Chemical & Life Science 
Engineering, tomorrow’s medications are moving 
toward manufacturing processes that shrink the 
environmental and industrial footprint as they 
expand global access to drugs. And those meds 
are likely to be more customized to the patient 
and easier to take.
“I would say that the theme of my lab is 
miniaturization for the purpose of personalized 
medicine,” Roper said. “By taking processes 
from the macro scale to the micro scale, we are 
able to bring science and engineering closer to 
the patient.”
Pharmacy on Demand, a project that Roper 
is working on with collaborators from the 
Massachusetts Institute of Technology, is an 
object lesson in these themes. In this case, the 
object is a pharmaceutical factory merely the 
size of a refrigerator.
Patients in hard-to-access places often 
have to wait for medicine – or go without it 
altogether. Pharmacy on Demand is working 
on an alternative approach based on small, 
configurable pharmaceutical manufacturing 
platforms that can ultimately be shipped to 
different locations to supply patients with locally 
produced, high-quality meds.
Such a strategy would expand access 
to pharmaceuticals worldwide, reduce 
environmental impact and make the 
manufacturing process safer by avoiding the 
burden of the construction of manufacturing 
sites.
“In my opinion, the biggest advantage of these 
miniature manufacturing facilities is footprint,” 
Roper said. “Take hydrogen, for example, 
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‘By taking processes 
from the macro scale to 
the micro scale, we are 
able to bring science and 
engineering closer to the 
patient,’ Roper says.
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which is highly flammable and explosive. If you 
have a big reactor with hydrogen under high 
pressure, there are huge safety parameters that 
must be accounted for, but a facility this size is 
intrinsically safer because there is much less 
hydrogen available to react at any one time.”
Roper hopes to initiate work in the area of 
biological catalysis that will streamline the 
pharmaceutical manufacturing process further.
“Another potential way to manufacture medicines 
is biologically,” Roper said. “An area I am 
interested in is biological catalysis of reactions, 
so eventually you are creating medicines in a 
biological host such as E. coli or ultimately even 
in a human cell.”
In this paradigm, the medicine is not a tablet 
from an amber-colored bottle, but a chemical 
process that transfers the manufacturing of the 
medicine to the patient’s body.
“In other words, if you string together chemical 
transformations that can be done by enzymes in 
a cell, you can effectively eliminate the external 
manufacturing footprint,” Roper said.
He sees other trends away from the production 
of medicines that patients take regularly and 
toward the creation of processes that play out 
in a patient’s body over time. These include 
commercial gene therapies like Strimvelis, 
GlaxoSmithKline’s recently approved treatment 
for severe combined immunodeficiency or 
“bubble boy disease.”
Roper also points to the development of long-
acting medicines that patients take only once 
every 60 to 90 days. When perfected, they may 
offer major advantages, including freedom from 
the stigma of disease and greater assurance that 
patients will actually take their prescriptions.
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“Patient compliance in pharmaceuticals is 
terrible, which reduces the effect of the medical 
treatment. Even in cancer treatment, patients 
will not always take their medicine when 
they are supposed to,” Roper said. Creating 
ways to increase patient compliance with 
treatment regimens is an important aspect of 
pharmaceutical research.
He noted an additional advantage to many of the 
next-generation drugs – one harder to quantify.
“There is a general improvement in patient 
quality of life,” Roper said. “These treatments 
come closer to being cures, so people have to 
spend less time feeling like a patient.” •
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Creating ways to 
increase patient 
compliance with 
treatment regimens is 
an important aspect of 
pharmaceutical research.
